Quarterly ResultMay 12, 2026, 04:08 PM
Opus Genetics Q1 Net Loss $(65.5M); Equity Shifts to Deficit
AI Summary
Opus Genetics reported a significant net loss of $(65.5) million for Q1 2026, a substantial increase from $(8.2) million in Q1 2025, primarily driven by a $(51.4) million fair value change in warrant liabilities. The company's total stockholders' equity shifted to a deficit of $(45.8) million from a positive $15.3 million at year-end 2025. Despite increased operating cash burn, cash and cash equivalents rose to $59.9 million, further bolstered by a subsequent $34.5 million financing from Oberland Capital.
Key Highlights
- Net loss for Q1 2026 was $(65.5) million, significantly up from $(8.2) million in Q1 2025.
- Fair value change in warrant liabilities resulted in a $(51.4) million expense in Q1 2026.
- Total stockholders' equity shifted to a deficit of $(45.8) million from $15.3 million.
- License and collaborations revenue decreased to $2.2 million from $4.4 million year-over-year.
- Research and development expenses increased to $10.6 million from $8.0 million year-over-year.
- Net cash used in operating activities increased to $(12.7) million from $(9.0) million year-over-year.
- Cash and cash equivalents stood at $59.9 million as of March 31, 2026.
- Received $34.5 million from a senior secured notes facility in April 2026.
Price Impact
More from IRD